| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/06/2003 | WO2002087556A3 Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality |
| 02/06/2003 | WO2002085337B1 Micellar drug delivery systems for hydrophobic drugs |
| 02/06/2003 | WO2002080940A3 Pharmacologically active strong acid solutions |
| 02/06/2003 | WO2002079146A3 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 02/06/2003 | WO2002078605A3 Premixed amiodarone parenteral solution and method for making the same |
| 02/06/2003 | WO2002070516A3 Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors |
| 02/06/2003 | WO2002067942A3 Methods of treating irritable bowel syndrome and functional dyspepsia |
| 02/06/2003 | WO2002067910A3 The use of antigestagens for inhibiting accelerated endometrial maturation during infertility treatment |
| 02/06/2003 | WO2002067851A3 Method for treating fibrotic diseases or other indications iiic |
| 02/06/2003 | WO2002066418A3 Process for the preparation of arylethanoldiamines useful as agonists of the beta-3-adrenoceptor |
| 02/06/2003 | WO2002064586A3 Heterocyclic inhibitors of erk2 and uses thereof |
| 02/06/2003 | WO2002061110A3 Nucleic acid derivatives |
| 02/06/2003 | WO2002060950A3 Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy |
| 02/06/2003 | WO2002060424A3 Methods of using and compositions comprising sibutramine metabolites optionally in combination with other pharmacologically active compounds |
| 02/06/2003 | WO2002059112A3 Pyrazole compounds useful as protein kinase inhibitors |
| 02/06/2003 | WO2002058686A3 Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes |
| 02/06/2003 | WO2002058535A3 Use of combretastatin a4 and its prodrugs as an immune enhancing therapy |
| 02/06/2003 | WO2002056826A3 Method for producing purified hematinic iron-saccharidic complex and product produced |
| 02/06/2003 | WO2002055065A3 Use of an ltb4 antagonist for the treatment and/or prevention of diseases caused by increased expression of mucin genes |
| 02/06/2003 | WO2002053555A3 Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists |
| 02/06/2003 | WO2002048134A3 Di-substituted aminomethyl chroman derivative beta-3 adrenoreceptor agonists |
| 02/06/2003 | WO2002046194A3 Substituted imidazopyridines |
| 02/06/2003 | WO2002046172A3 Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| 02/06/2003 | WO2002046141A3 Coumpounds of the formula r1-x-y-z-nr2r3 as abca-1 elevating agents against coronary artery disease or atherosclerosis |
| 02/06/2003 | WO2002041843A3 Antiinflammation agents |
| 02/06/2003 | WO2002039995A9 Combination therapy for estrogen-dependent disorders |
| 02/06/2003 | WO2002039953A3 Texaphyrin coordination compounds and uses thereof |
| 02/06/2003 | WO2002036558A3 Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation |
| 02/06/2003 | WO2002030937A3 Labeled resiniferatoxin derivatives for use in vanilloid receptor binding assay |
| 02/06/2003 | WO2002030355A3 Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase |
| 02/06/2003 | WO2002026240A9 Inhibition of antigen presentation with poorly catabolized polymers |
| 02/06/2003 | WO2002021996A3 Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators |
| 02/06/2003 | WO2002020722A3 Methods and compositions for in vitro targeting |
| 02/06/2003 | WO2002017895A3 Use of an aldosterone receptor antagonist to improve cognitive function |
| 02/06/2003 | WO2002016602A3 Compositions and methods for the diagnosis and treatment of tumor |
| 02/06/2003 | WO2002013870A3 Formulation for administering therapeutic lipophilic molecules |
| 02/06/2003 | WO2002010137A9 Indazole derivatives as jnk inhibitors |
| 02/06/2003 | WO2002007733A3 Method for enhancing bone mineral density gain by administration of raloxifene |
| 02/06/2003 | WO2002002645A8 COLD WATER SOLUBLE β-GLUCAN PRODUCT AND PROCESS FOR PREPARING THE SAME |
| 02/06/2003 | WO2002002095A3 Compositions for treating bacterial infections containing oxazolidinone compound, sulbactam and an ampicillin |
| 02/06/2003 | WO2002002093A3 Combination containing an antifolate and methylmalonic acid lowering agent |
| 02/06/2003 | WO2001093744A3 Controlling attention and memory by altering neuronal carbonic anhydrase activity |
| 02/06/2003 | WO2001088199A3 Identification and modulationof of a t helper-1 and t helper-2 cells |
| 02/06/2003 | WO2001080862A9 Use of mmp inhibitors in filtering blebs and ischemia |
| 02/06/2003 | WO2000067699A3 Pharmaceutical compositions for treating malaria |
| 02/06/2003 | WO2000050040A8 Method and composition for prevention of scar formation in glaucoma filtration bleb and drainage fistula |
| 02/06/2003 | US20030028169 Topical delivery of L-arginine to cause beneficial effects |
| 02/06/2003 | US20030028038 Semi-synthetic taxanes with antitumor and antiangiogenetic activities |
| 02/06/2003 | US20030028036 Cyclooxygenase-2 (COX-2); preparing 4-(4-alkylsulfonyl-phenyl)-2,5-dihydro-furan-2-ones by reacting 2-alkoxy-2-(4-alkylsulfonylphenyl)oxetane with a substituted carboxylic acid and then cyclizing that product |
| 02/06/2003 | US20030028034 Nematicidal pyrazoles |
| 02/06/2003 | US20030028030 Oxidation of a thioether to a sulfoxide using sodium percarbonate and a molybdenum salt as catalyst; making lansoprazole, omeprazole, rabeprazole, and pantoprazole |
| 02/06/2003 | US20030028029 Process for production of piperidine derivatives |
| 02/06/2003 | US20030028028 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels |
| 02/06/2003 | US20030028026 Nitrate salts of Salbutamol, Cetirizine, Loratadine, Terfenadine, Emedastine, Ketotifen, Nedocromil, Ambroxol, Dextromethorphan, Dextorphan, Isoniazide, Erythromycin, and Pyrazinamide; respiratory system pathology treatment |
| 02/06/2003 | US20030028025 Pediatric formulation of gatifloxacin |
| 02/06/2003 | US20030028021 Chemical compounds |
| 02/06/2003 | US20030028018 Treating diseases characterized by activity of vascular endothelial growth factor receptor tyrosine kinases such as cancer |
| 02/06/2003 | US20030028008 Nucleotide sequences coding polypeptide for use in the treatment of urogenital, tumor, antherosclerotic and kidney disorders |
| 02/06/2003 | US20030028006 Cytokine receptor common gamma chain like |
| 02/06/2003 | US20030027999 143 human secreted proteins |
| 02/06/2003 | US20030027983 Transport protein for use in the treatment of blood, hypertensive and epileptic disorders |
| 02/06/2003 | US20030027870 Fullerene derivative that carries one water-solublizing substituent. |
| 02/06/2003 | US20030027869 Amine compounds and inhibiting neurotransmitter reuptake |
| 02/06/2003 | US20030027868 Aminoacetalization of camphor by reacting with NH4OH and suspending product in NaCl; preparation having a basic pH is then neutralised with nitric acid; product is an analogue of human cytokines |
| 02/06/2003 | US20030027867 Use of R-NSAID compounds for anti-HIV treatment |
| 02/06/2003 | US20030027866 Prevention of apoptosis in non-cancerous cells |
| 02/06/2003 | US20030027864 Compositions comprising a compound of low solubility and a lipophilic amino acid derivative, uses thereofand process for dissolving a compound of low solubility |
| 02/06/2003 | US20030027863 Such as restenosis and atherosclerosis. |
| 02/06/2003 | US20030027861 6-Methoxy-2-naphthylacetic acid prodrugs |
| 02/06/2003 | US20030027860 6-Methoxy-2-naphthylacetic acid prodrugs |
| 02/06/2003 | US20030027859 3-aryl-2-hydroxypropionic acid derivative I |
| 02/06/2003 | US20030027858 Emulsion vehicle for poorly soluble drugs |
| 02/06/2003 | US20030027856 Tolterodine metabolites |
| 02/06/2003 | US20030027855 Preparation of a derivative or analog of baccatin III or 10-desacetyl baccatin III having a C9 hydroxy substituent by selective reduction of the C9 keto compound |
| 02/06/2003 | US20030027854 Methods for the treatment of itching comprising administering PGD2 receptor antagonists |
| 02/06/2003 | US20030027853 3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure |
| 02/06/2003 | US20030027852 Substituted pyrrolidine-2,3,4-trione 3-oxime deerivatives which are active as NMDA receptor antagonists |
| 02/06/2003 | US20030027851 Readily soluble crystal modification; specific X-ray diffraction pattern obtained with a focusing Debye-Scherrer beam and Cu-K alpha 1-radiation |
| 02/06/2003 | US20030027848 Stabilized formulations |
| 02/06/2003 | US20030027847 Carboxyformylacetamide derivatives for treatment of AIDS or ARC |
| 02/06/2003 | US20030027846 Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents |
| 02/06/2003 | US20030027845 Ether derivatives useful as inhibitors of PDE4 isozymes |
| 02/06/2003 | US20030027844 Component a): one or more conventional anti-ulcer products; component b): organic compounds containing the -ONO2 function, or inorganic compounds containing the -NO group, that are nitric oxide donors |
| 02/06/2003 | US20030027843 Remedies or preventives for digestive diseases containing diaminotrifluoromethypyridine derivatives |
| 02/06/2003 | US20030027841 Percutaneously applicable preparation and suppository containing an antidementia medicament |
| 02/06/2003 | US20030027840 Estrogen receptor modulators |
| 02/06/2003 | US20030027839 Farnesyl protein transferase inhiitors for treating breast cancer |
| 02/06/2003 | US20030027837 Pharmaceutical compositions comprising quinapril magnesium |
| 02/06/2003 | US20030027836 Arylalkoxy-substituted tetrahydroisoquinoline-3-carboxylic acids or esters |
| 02/06/2003 | US20030027835 Trimebutine, N-desmethyltrimebutine, their metabolites or their stereoisomers and an opioid analgesic for treating pain or nociception. |
| 02/06/2003 | US20030027834 Modulating a pharmacological response from the ORL1 receptor for treating chronic pain |
| 02/06/2003 | US20030027833 Compositions and delivery systems for administration of a local anesthetic agent |
| 02/06/2003 | US20030027832 4-Phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives |
| 02/06/2003 | US20030027831 Arylpiperzine derivatives are useful for treatment of anxiety, depression, hypertension, cognitive disorders, sexual dysfunction, brain trauma, memory loss, eating disorders, obesity, substance abuse, and obsessive-compulsive diseases |
| 02/06/2003 | US20030027828 Malonamid and malonamic ester derivatives with antithrombotic activity, their preparation, and their use |
| 02/06/2003 | US20030027827 Treating racemic 2-(chlorophenyl)-2-hydroxy-3,5,5-trimethyl-morpholinol with p-toluyl-L-tartaric acid(a chiral acid) in a suitable solvent to form a mixture of diastereomeric salts; isolating the salt, reacting with base |
| 02/06/2003 | US20030027824 Pyrazolopyrimidinones for the treatment of female sexual dysfunction |
| 02/06/2003 | US20030027821 Administering 2-oxy substituted benzoxazin-5-one derivative to a human or animal for the prevention or treatment of obesity or an obesity related disorder |
| 02/06/2003 | US20030027820 Method for treating fibrotic diseases or other indications V |
| 02/06/2003 | US20030027819 Administering to an animal in need for protease inhibition an effective amount of substituted heterobicyclic compound containing amino acid side chains |